Pralsetinib (BLU-667)

Pralsetinib (BLU-667) (CAS No.: 2097132-94-8) is a synthetic small molecule research inhibitor broadly categorized within targeted kinase modulator libraries for oncology focused translational studies, with a functional profile characterized by high selectivity and potency against RET kinase driven signaling biology in mechanistic systems. Available evidence indicates robust inhibition of wild type RET and representative oncogenic RET variants including V804L, V804M, and M918T, as well as RET fusion associated signaling such as CCDC6 RET, with activity reported in the subnanomolar to low nanomolar range, supporting its use as a precision tool for interrogation of RET dependent phosphorylation networks and downstream pathway regulation, including MAPK and PI3K AKT axis related signal propagation in engineered or endogenous RET altered cellular contexts. In biomedical research workflows, this compound is commonly used to define target dependency, benchmark RET pathway suppression, evaluate resistance associated kinase gatekeeper or activation loop alterations, and support structure activity and combination screening paradigms in cell based assays and preclinical animal studies, while concentration and dose selection are determined by model specific pharmacology, assay format, exposure duration, and the scientific objectives of each experimental design.